Yu Mei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Mei has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Haiyan Liu
Immunology Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore
15 shared publications - Zuhairah Binte Hanafi
Immunology Program, Life Sciences Institute, Immunology Translational Research Program, and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456, Singapore
14 shared publications - Huey Yee Teo
Immunology Program, Life Sciences Institute, Immunology Translational Research Program, and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456, Singapore
13 shared publications - Kylie Su Mei Yong
Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (ASTAR), Singapore 138673, Singapore
13 shared publications - Qingfeng Chen
Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
13 shared publications - Ying Zhu
Immunology Program, Life Sciences Institute, Immunology Translational Research Program, and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456, Singapore
13 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 579-593
A PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately
Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold’ tumours. To overcome this limitation, we developed a dual targeting human PD1‐CD137L (hPD1‐CD137L) fusion protein that blocks PD‐L1–PD1 inhibitory signalling and simultaneously delivers CD137‐mediated T cell costimulation. The fusion protein was produced with high purity and demonstrated specific binding to PD‐L1‐expressing tumour cells and CD137‐positive T cells. The hPD1‐CD137L retained a stable multimeric structure under acidic conditions and during prolonged storage, supporting its suitability for systemic administration and activity within the tumour microenvironment. Functionally, hPD1‐CD137L enhanced T cell activation, as evidenced by increased NF‐κB signalling and activation marker expression, and promoted robust tumour cell cytolysis in both 2D and 3D co‐culture systems. Anti‐tumour activity was observed across multiple tumour models with varying PD‐L1 expression, including nasopharyngeal carcinoma (NPC), rhabdomyosarcoma, lung carcinoma and patient‐derived colorectal cancer organoids. Notably, hPD1‐CD137L enhanced cytolysis of C666 NPC cells by patient‐derived tumour‐infiltrating lymphocytes at low effector‐to‐target ratios, and was more potent than a combination of an anti‐PD‐1 antibody and a CD137 agonist. In vivo, PBMC‐humanised NSG mice tolerated hPD1‐CD137L without significant weight loss, systemic inflammation or survival impact. Subsequent efficacy study in PBMC‐humanised, Rd18 rhabdomyosarcoma‐engrafted or C666 nasopharyngeal carcinoma‐engrafted NSG mice showed tumour growth suppression without overt toxicity. This study validates a human PD1‐CD137L fusion protein as a potent drug candidate for cancer immunotherapy.
- 10 August 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 579-593
Open AccessA PD1 ‐ CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD ‐ L1 and CD137 Separately
Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold’ tumours. To overcome this limitation, we developed a dual targeting human PD1‐CD137L (hPD1‐CD137L) fusion protein that blocks PD‐L1–PD1 inhibitory signalling and simultaneously delivers CD137‐mediated T cell costimulation. The fusion protein was produced with high purity and demonstrated specific binding to PD‐L1‐expressing tumour cells and CD137‐positive T cells. The hPD1‐CD137L retained a stable multimeric structure under acidic conditions and during prolonged storage, supporting its suitability for systemic administration and activity within the tumour microenvironment. Functionally, hPD1‐CD137L enhanced T cell activation, as evidenced by increased NF‐κB signalling and activation marker expression, and promoted robust tumour cell cytolysis in both 2D and 3D co‐culture systems. Anti‐tumour activity was observed across multiple tumour models with varying PD‐L1 expression, including nasopharyngeal carcinoma (NPC), rhabdomyosarcoma, lung carcinoma and patient‐derived colorectal cancer organoids. Notably, hPD1‐CD137L enhanced cytolysis of C666 NPC cells by patient‐derived tumour‐infiltrating lymphocytes at low effector‐to‐target ratios, and was more potent than a combination of an anti‐PD‐1 antibody and a CD137 agonist. In vivo, PBMC‐humanised NSG mice tolerated hPD1‐CD137L without significant weight loss, systemic inflammation or survival impact. Subsequent efficacy study in PBMC‐humanised, Rd18 rhabdomyosarcoma‐engrafted or C666 nasopharyngeal carcinoma‐engrafted NSG mice showed tumour growth suppression without overt toxicity. This study validates a human PD1‐CD137L fusion protein as a potent drug candidate for cancer immunotherapy.
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Nur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma
Despite promising development as emerging "off-the-shelf" therapeutics against cancer, natural killer (NK) cells still faced considerable challenges in the solid tumor microenvironment (TME), including poor penetrance and immuno-suppression. Here, we employ spatial and single-cell transcriptomics to reveal a role for Nur77 in NK cell-mediated immunity against hepatocellular carcinoma (HCC). Orthogonal analysis of human and mouse HCC tumors indicate that the expression of NR4A1, encoding Nur77, is associated with NK cell proliferation, activation of the immunostimulatory AP-1 gene regulons, and better disease-free survival in HCC. Conditional ablation of Nr4a1 in NK cells perturbs their homeostasis and accelerates tumor progression in multiple tumor models. Conversely, the agonistic activation of Nur77 in NK cells ex-vivo or in-vivo enhances their anti-tumor functions. Mechanistically, downstream functional assays confirm that Nur77 activation attenuates CD36 expression in NK cells and confers resistance against oxLDL-mediated immunosuppression in the TME. Collectively, our findings highlight the potential of harnessing Nur77 agonism in improving NK cell-based immunotherapy against HCC.
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNur77 agonism invigorates Natural Killer cell immunity against hepatocellular carcinoma
Despite promising development as emerging "off-the-shelf" therapeutics against cancer, natural killer (NK) cells still faced considerable challenges in the solid tumor microenvironment (TME), including poor penetrance and immuno-suppression. Here, we employ spatial and single-cell transcriptomics to reveal a role for Nur77 in NK cell-mediated immunity against hepatocellular carcinoma (HCC). Orthogonal analysis of human and mouse HCC tumors indicate that the expression of NR4A1, encoding Nur77, is associated with NK cell proliferation, activation of the immunostimulatory AP-1 gene regulons, and better disease-free survival in HCC. Conditional ablation of Nr4a1 in NK cells perturbs their homeostasis and accelerates tumor progression in multiple tumor models. Conversely, the agonistic activation of Nur77 in NK cells ex-vivo or in-vivo enhances their anti-tumor functions. Mechanistically, downstream functional assays confirm that Nur77 activation attenuates CD36 expression in NK cells and confers resistance against oxLDL-mediated immunosuppression in the TME. Collectively, our findings highlight the potential of harnessing Nur77 agonism in improving NK cell-based immunotherapy against HCC.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Supplementary Figures and Table
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Supplementary Figures and Table
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
Supplementary Figures and Table
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
Supplementary Figures and Table
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
Supplementary Figures and Table
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
Supplementary Figures and Table
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pre-treatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro-expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 pre-activated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 pre-activated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 pre-activation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell-cell contact- and ICAM-1-dependent manner. Furthermore, the adoptive transfer of IL12/18/21 pre-activated γδT cells could overcome the resistance to anti-PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced anti-tumor function of adoptively transferred IL12/18/21 pre-activated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti-PD-L1, suggesting a CD8+ T cell-dependent mechanism. Taken together, IL12/18/21 pre-activation can promote γδT cell anti-tumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pre-treatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro-expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 pre-activated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 pre-activated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 pre-activation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell-cell contact- and ICAM-1-dependent manner. Furthermore, the adoptive transfer of IL12/18/21 pre-activated γδT cells could overcome the resistance to anti-PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced anti-tumor function of adoptively transferred IL12/18/21 pre-activated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti-PD-L1, suggesting a CD8+ T cell-dependent mechanism. Taken together, IL12/18/21 pre-activation can promote γδT cell anti-tumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.
- Open Access
- 26 February 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (3) , 113835
IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment
- 26 February 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (3) , 113835
Open AccessIL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Supplementary Figures and Table
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Supplementary Figures and Table
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pretreatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro–expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 preactivated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 preactivated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 preactivation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell–cell contact- and ICAM-1–dependent manner. Furthermore, the adoptive transfer of IL12/18/21 preactivated γδT cells could overcome the resistance to anti–PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced antitumor function of adoptively transferred IL12/18/21 preactivated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti–PD-L1, suggesting a CD8+ T cell–dependent mechanism. Taken together, IL12/18/21 preactivation can promote γδT cell antitumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pretreatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro–expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 preactivated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 preactivated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 preactivation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell–cell contact- and ICAM-1–dependent manner. Furthermore, the adoptive transfer of IL12/18/21 preactivated γδT cells could overcome the resistance to anti–PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced antitumor function of adoptively transferred IL12/18/21 preactivated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti–PD-L1, suggesting a CD8+ T cell–dependent mechanism. Taken together, IL12/18/21 preactivation can promote γδT cell antitumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pretreatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro–expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 preactivated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 preactivated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 preactivation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell–cell contact- and ICAM-1–dependent manner. Furthermore, the adoptive transfer of IL12/18/21 preactivated γδT cells could overcome the resistance to anti–PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced antitumor function of adoptively transferred IL12/18/21 preactivated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti–PD-L1, suggesting a CD8+ T cell–dependent mechanism. Taken together, IL12/18/21 preactivation can promote γδT cell antitumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
γδT cells are promising candidates for cellular immunotherapy due to their immune regulation through cytokine production and MHC-independent direct cytotoxicity against a broad spectrum of tumors. However, current γδT cell-based cancer immunotherapy has limited efficacy, and novel strategies are needed to improve clinical outcomes. Here, we report that cytokine pretreatment with IL12/18, IL12/15/18, IL12/18/21, and IL12/15/18/21 effectively enhanced the activation and cytotoxicity of in vitro–expanded murine and human γδT cells. However, only adoptive transfer of IL12/18/21 preactivated γδT cells significantly inhibited tumor growth in a murine melanoma model and a hepatocellular carcinoma model. Both IL12/18/21 preactivated antibody-expanded and zoledronate-expanded human γδT cells effectively controlled tumor growth in a humanized mouse model. IL12/18/21 preactivation promoted γδT cell proliferation and cytokine production in vivo and enhanced IFNγ production and activation of endogenous CD8+ T cells in a cell–cell contact- and ICAM-1–dependent manner. Furthermore, the adoptive transfer of IL12/18/21 preactivated γδT cells could overcome the resistance to anti–PD-L1 therapy, and the combination therapy had a synergistic effect on the therapeutic outcomes. Moreover, the enhanced antitumor function of adoptively transferred IL12/18/21 preactivated γδT cells was largely diminished in the absence of endogenous CD8+ T cells when administered alone or in combination with anti–PD-L1, suggesting a CD8+ T cell–dependent mechanism. Taken together, IL12/18/21 preactivation can promote γδT cell antitumor function and overcome the resistance to checkpoint blockade therapy, indicating an effective combinational cancer immunotherapeutic strategy.